



## Clinical trial results:

## **BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age**

### **Summary**

EudraCT number	2014-000464-17
Trial protocol	GB CZ BE IT NL NO PL FR
Global end of trial date	10 February 2022

### **Results information**

Result version number	v1
This version publication date	20 August 2022
First version publication date	20 August 2022

### **Trial information**

#### **Trial identification**

Sponsor protocol code	191622-137
-----------------------	------------

#### **Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02097121
WHO universal trial number (UTN)	-

Notes:

#### **Sponsors**

Sponsor organisation name	Allergan
Sponsor organisation address	2525 Dupont Drive, Irvine, CA, United States, 92612
Public contact	Global Medical Services, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>
Scientific contact	Global Medical Services, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>

Notes:

#### **Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 February 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	10 February 2022
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

This was a multicenter, randomized, double-blind, parallel-group, multiple-dose study to evaluate the efficacy and safety of BOTOX in adolescents with urinary incontinence due to overactive bladder (OAB) with inadequate management with anticholinergic therapy. Subjects were randomized in a 1:1:1 ratio to receive a single Tx of 25 U, 50 U, or 100 U BOTOX (not to exceed 6 U/kg) on Day 1, were seen after each treatment at Wks 2, 6, and 12 post-treatment, and thereafter at alternating telephone and clinic visits every 6 weeks until they qualified for further retreatment/exited the study. Subjects could receive multiple treatments dependent upon the number and timing of patient requests/qualification for retreatment. At each retreatment the investigator could keep the dose the same or increase it one dose level in a blinded fashion. Subjects exited the study once 96 weeks have elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment had occurred.

Protection of trial subjects:

Written informed consent was to be obtained from each patient and/or from the patient's legally authorized representative prior to initiating any study-related activities or procedures. If the patient was under the legal age of consent, the consent form must have been signed by the legally authorized representative in accordance with the relevant country and local regulatory requirements.

Written parental/legally authorized representative informed consent in addition to a separate written minor consent and/or assent (in accordance with any applicable state and local laws/regulations) was required for each minor study patient prior to study enrollment or any study-related procedures in the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 May 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Belgium: 10
Country: Number of subjects enrolled	Canada: 11
Country: Number of subjects enrolled	Czechia: 2
Country: Number of subjects enrolled	United Kingdom: 21
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Poland: 4
Country: Number of subjects enrolled	United States: 4

Worldwide total number of subjects	56
EEA total number of subjects	17

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	56
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study included a 28-day screening period.

### Period 1

Period 1 title	Overall Study
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Assessor

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Botox 25 U
------------------	------------

Arm description:

Subjects were to initially receive a single treatment of 25 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.

Arm type	Experimental
Investigational medicinal product name	BOTOX®
Investigational medicinal product code	9060X
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.

<b>Arm title</b>	Botox 50 U
------------------	------------

Arm description:

Subjects were to initially receive a single treatment of 50 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	BOTOX®
Investigational medicinal product code	9060X
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.

<b>Arm title</b>	Botox 100 U
------------------	-------------

**Arm description:**

Subjects were to initially receive a single treatment of 100 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.

Arm type	Experimental
Investigational medicinal product name	BOTOX®
Investigational medicinal product code	9060X
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.

<b>Number of subjects in period 1</b>	Botox 25 U	Botox 50 U	Botox 100 U
Started	19	18	19
Completed	12	12	9
Not completed	7	6	10
Adverse event, non-fatal	-	1	-
Other, not specified	4	2	3
Lost to follow-up	1	1	2
Lack of efficacy	2	1	3
Withdrawal by subject	-	1	2

## Period 2

Period 2 title	BOTOX-treated population
Is this the baseline period?	Yes <sup>[1]</sup>
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Assessor

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	BOTOX 25 U (BOTOX-Treated Population)

### Arm description:

Subjects initially received a single treatment of 25 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.

Arm type	Experimental
Investigational medicinal product name	BOTOX®
Investigational medicinal product code	9060X
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

### Dosage and administration details:

Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.

<b>Arm title</b>	BOTOX 50 U (BOTOX-Treated Population)
------------------	---------------------------------------

### Arm description:

Subjects initially received a single treatment of 50 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.

Arm type	Experimental
Investigational medicinal product name	BOTOX®
Investigational medicinal product code	9060X
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

### Dosage and administration details:

Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to

be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.

<b>Arm title</b>	BOTOX 100 U (BOTOX-Treated Population)
Arm description:	
Subjects initially received a single treatment of 100 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.	
Arm type	Experimental
Investigational medicinal product name	BOTOX®
Investigational medicinal product code	9060X
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.

**Notes:**

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: The BOTOX-treated population included all subjects enrolled into the study who received at least 1 BOTOX treatment and was used for safety and efficacy analyses.

<b>Number of subjects in period 2<sup>[2]</sup>[3]</b>	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)
Started	12	12	9
Completed	18	17	20

Joined	6	5	11
BOTOX-treated subjects	6	5	10
Transferred in from other group/arm	-	-	1

**Notes:**

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The BOTOX-treated population included all subjects enrolled into the study who received at least 1 BOTOX treatment. Analyses were based on the treatment actually received in each treatment cycle; numbers of subjects per treatment arm differed from the initially enrolled groups. In addition, one subject who enrolled in the BOTOX 50 U group did not receive treatment.

[3] - The number of subjects transferring in and out of the arms in the period are not the same. It is expected the net number of transfers in and out of the arms in a period, will be zero.

Justification: The BOTOX-treated population included all subjects enrolled into the study who received at least 1 BOTOX treatment. One subject who enrolled in the BOTOX 50 U group did not receive treatment.

Subjects could move from lower dose groups to higher dose groups upon blinded request, resulting in shifting numbers of subjects per treatment group, differing from the initially enrolled groups. Analyses were based on the treatment actually received in each treatment cycle.



## Baseline characteristics

### Reporting groups

Reporting group title	BOTOX 25 U (BOTOX-Treated Population)
-----------------------	---------------------------------------

Reporting group description:

Subjects initially received a single treatment of 25 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.

Reporting group title	BOTOX 50 U (BOTOX-Treated Population)
-----------------------	---------------------------------------

Reporting group description:

Subjects initially received a single treatment of 50 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.

Reporting group title	BOTOX 100 U (BOTOX-Treated Population)
-----------------------	--

Reporting group description:

Subjects initially received a single treatment of 100 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.

Reporting group values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)
Number of subjects	18	17	20
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	18	17	20
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	13.7	14.3	14.0
standard deviation	± 1.49	± 1.86	± 1.75
Gender categorical Units: Subjects			
Female	16	17	14
Male	2	0	6

Race			
Units: Subjects			
White	12	12	17
Black or African American	0	0	0
Asian	0	1	0
Hispanic	0	0	0
Other	1	1	1
Not Reported	2	1	1
Unknown	3	2	1
Daily Frequency of Daytime Urinary Incontinence Episodes			
A bladder diary was used to log each daytime urgency episode over 2 consecutive days during screening.			
Units: number of episodes			
arithmetic mean	5.29	3.54	3.64
standard deviation	± 3.447	± 2.696	± 2.951

<b>Reporting group values</b>	Total		
Number of subjects	55		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	55		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	47		
Male	8		
Race			
Units: Subjects			
White	41		
Black or African American	0		
Asian	1		
Hispanic	0		
Other	3		
Not Reported	4		
Unknown	6		
Daily Frequency of Daytime Urinary Incontinence Episodes			
A bladder diary was used to log each daytime urgency episode over 2 consecutive days during screening.			

Units: number of episodes			
arithmetic mean			
standard deviation	-		

## End points

### End points reporting groups

Reporting group title	Botox 25 U
Reporting group description: Subjects were to initially receive a single treatment of 25 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.	
Reporting group title	Botox 50 U
Reporting group description: Subjects were to initially receive a single treatment of 50 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.	
Reporting group title	Botox 100 U
Reporting group description: Subjects were to initially receive a single treatment of 100 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.	
Reporting group title	BOTOX 25 U (BOTOX-Treated Population)
Reporting group description: Subjects initially received a single treatment of 25 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.	
Reporting group title	BOTOX 50 U (BOTOX-Treated Population)
Reporting group description: Subjects initially received a single treatment of 50 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.	
Reporting group title	BOTOX 100 U (BOTOX-Treated Population)
Reporting group description: Subjects initially received a single treatment of 100 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits were to occur at Weeks 2, 6, and 12. Thereafter, those who did not request retreatment were to have alternating telephone and clinic follow-up visits every 6 weeks until they exited the study. Subjects were to exit the study once 96 weeks had elapsed since entry on Day 1 and at least 12 weeks follow-up since their last study treatment has occurred.	
Subject analysis set title	BOTOX-treated population
Subject analysis set type	Safety analysis
Subject analysis set description: All participants enrolled into the study who received at least 1 BOTOX treatment	

## Primary: Change From Study Baseline in the Daily Normalized Daytime Average Number of Urinary Incontinence Episodes in Treatment Cycle 1

End point title	Change From Study Baseline in the Daily Normalized Daytime Average Number of Urinary Incontinence Episodes in Treatment Cycle 1
-----------------	---

End point description:

Urinary incontinence was defined as involuntary loss of urine as recorded by the participant in a bladder diary during 2 consecutive days in the week prior to the study visit (normalized to a 12 hour daytime period). Daytime is defined as the time between waking up to start the day and going to bed to sleep for the night. The number of daily daytime incontinence episodes were averaged during the 2-day period. A negative change from Baseline indicates improvement. Data are summarized per the respective treatments that participants received in the corresponding treatment cycle.

End point type	Primary
----------------	---------

End point timeframe:

From Baseline to 2 consecutive days in the week prior to Week 12 in Treatment Cycle 1

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[1]</sup>	17 <sup>[2]</sup>	20 <sup>[3]</sup>	
Units: urinary incontinence episodes per day				
least squares mean (standard error)	-1.37 (± 0.801)	-0.97 (± 0.811)	-2.35 (± 0.746)	

Notes:

[1] - Subjects with analysis values at both baseline and Week 12

[2] - Subjects with analysis values at both baseline and Week 12

[3] - Subjects with analysis values at both baseline and Week 12

## Statistical analyses

Statistical analysis title	Treatment Difference of 100 U versus 25 U
----------------------------	---

Statistical analysis description:

Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group as factor. A hierarchical analysis strategy to adjust for multiplicity was used.

Comparison groups	BOTOX 25 U (BOTOX-Treated Population) v BOTOX 100 U (BOTOX-Treated Population)
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3802
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.203
upper limit	1.243
Variability estimate	Standard error of the mean
Dispersion value	1.107

<b>Statistical analysis title</b>	Treatment Difference of 50 U versus 25 U
Statistical analysis description: Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group as factor. A hierarchical analysis strategy to adjust for multiplicity was used.	
Comparison groups	BOTOX 25 U (BOTOX-Treated Population) v BOTOX 50 U (BOTOX-Treated Population)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.733
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.921
upper limit	2.712
Variability estimate	Standard error of the mean
Dispersion value	1.154

## Secondary: Change From Study Baseline in the Daily Average Frequency of Normalized Daytime Micturition Episodes

End point title	Change From Study Baseline in the Daily Average Frequency of Normalized Daytime Micturition Episodes
-----------------	--

End point description:

Micturition was defined as toilet voids recorded by the participant in a bladder diary during 2 consecutive days in the week prior to the study visit (normalized to a 12 hour daytime period). Daytime is defined as the time between waking up to start the day and going to bed to sleep for the night. The number of daily daytime micturition episodes were averaged during the 2-day period. A negative change from Baseline indicates improvement. Data are summarized per the respective treatments that participants received in the corresponding treatment cycle.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to 2 consecutive days in the week prior to Week 12 in Treatment Cycle 1

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[4]</sup>	17 <sup>[5]</sup>	20 <sup>[6]</sup>	
Units: micturition episodes per day				
least squares mean (standard error)	-1.84 (± 1.027)	0.31 (± 1.014)	-1.02 (± 0.983)	

Notes:

[4] - Subjects with analysis values at both baseline and Week 12

[5] - Subjects with analysis values at both baseline and Week 12

[6] - Subjects with analysis values at both baseline and Week 12

## Statistical analyses

<b>Statistical analysis title</b>	Treatment Difference of 100 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of $\leq 6$ episodes or $> 6$ episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.	
Comparison groups	BOTOX 100 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5743
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.082
upper limit	3.713
Variability estimate	Standard error of the mean
Dispersion value	1.442

<b>Statistical analysis title</b>	Treatment Difference of 50 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of $\leq 6$ episodes or $> 6$ episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.	
Comparison groups	BOTOX 50 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1451
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	2.15

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.769
upper limit	5.078
Variability estimate	Standard error of the mean
Dispersion value	1.455

## Secondary: Change From Study Baseline in the Daily Average Frequency of Normalized Daytime Urgency Episodes

End point title	Change From Study Baseline in the Daily Average Frequency of Normalized Daytime Urgency Episodes
End point description:	
Participants recorded daytime urgency episodes in a bladder diary during 2 consecutive days in the week prior to the study visit (normalized to a 12 hour daytime period). Daytime is defined as the time between waking up to start the day and going to bed to sleep for the night. The number of daily daytime urgency episodes were averaged during the 2-day period. A negative change from Baseline indicates improvement. Data are summarized per the respective treatments that participants received in the corresponding treatment cycle.	
End point type	Secondary
End point timeframe:	
From Baseline to 2 consecutive days in the week prior to Week 12 in Treatment Cycle 1	

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[7]</sup>	17 <sup>[8]</sup>	20 <sup>[9]</sup>	
Units: urgency episodes per day				
least squares mean (standard error)	-1.85 (± 1.014)	-1.78 (± 0.998)	-2.18 (± 0.945)	

Notes:

[7] - Subjects with analysis values at both baseline and Week 12

[8] - Subjects with analysis values at both baseline and Week 12

[9] - Subjects with analysis values at both baseline and Week 12

## Statistical analyses

Statistical analysis title	Treatment Difference of 100 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of ≤ 6 episodes or > 6 episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.	
Comparison groups	BOTOX 100 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)



Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8206
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.205
upper limit	2.551
Variability estimate	Standard error of the mean
Dispersion value	1.434

<b>Statistical analysis title</b>	Treatment Difference of 50 U versus 25 U
-----------------------------------	--

Statistical analysis description:

Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of  $\leq 6$  episodes or  $> 6$  episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.

Comparison groups	BOTOX 25 U (BOTOX-Treated Population) v BOTOX 50 U (BOTOX-Treated Population)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9604
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.807
upper limit	2.95
Variability estimate	Standard error of the mean
Dispersion value	1.434

**Secondary: Percentage of Participants With Night Time Urinary Incontinence**

End point title	Percentage of Participants With Night Time Urinary Incontinence
-----------------	---

End point description:

Urinary incontinence was defined as involuntary loss of urine. Participants recorded night time urinary incontinence episodes in a bladder diary during 2 consecutive days in the week prior to the study visit. Night time is defined as the time between going to bed to sleep for the night and waking up to start the next day. The number of daily night time urinary incontinence episodes were averaged during the 2-day period. Data are summarized per the respective treatments that participants received in the corresponding treatment cycle.

End point type	Secondary
End point timeframe:	
From Baseline to 2 consecutive days in the week prior to Week 12 in Treatment Cycle 1	

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[10]</sup>	17 <sup>[11]</sup>	20 <sup>[12]</sup>	
Units: percentage of participants				
number (not applicable)				
Baseline—0 nights	22.2	52.9	35.0	
Baseline—1 night	27.8	11.8	15.0	
Baseline—2 nights	50.0	35.3	50.0	
Week 12—0 nights	50.0	76.5	50.0	
Week 12—1 night	22.2	5.9	15.0	
Week 12—2 nights	27.8	17.6	35.0	

Notes:

[10] - Subjects with analysis values at both baseline and Week 12

[11] - Subjects with analysis values at both baseline and Week 12

[12] - Subjects with analysis values at both baseline and Week 12

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Study Baseline in the Daily Average Volume Voided Per Micturition (mL)

End point title	Change From Study Baseline in the Daily Average Volume Voided Per Micturition (mL)
-----------------	--

End point description:

The volume per micturition was derived from the total urine volume voided over 1 daytime period during the 2-day bladder diary collection period divided by the number of voids in the same daytime period. Daytime is defined as the time between waking up to start the day and going to bed to sleep for the night. A negative change from Baseline indicates improvement. Data are summarized per the respective treatments that participants received in the corresponding treatment cycle.

End point type	Secondary
End point timeframe:	
From Baseline to 2 consecutive days in the week prior to Week 12 in Treatment Cycle 1	

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[13]</sup>	17 <sup>[14]</sup>	20 <sup>[15]</sup>	
Units: mL				
least squares mean (standard error)	-9.17 (±	24.94 (±	26.16 (±	

Notes:

[13] - Subjects with analysis values at both baseline and Week 12

[14] - Subjects with analysis values at both baseline and Week 12

[15] - Subjects with analysis values at both baseline and Week 12

## Statistical analyses

Statistical analysis title	Treatment Difference of 100 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of $\leq 6$ episodes or $> 6$ episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.	
Comparison groups	BOTOX 100 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1174
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	35.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.207
upper limit	79.873
Variability estimate	Standard error of the mean
Dispersion value	22.175

Statistical analysis title	Treatment Difference of 50 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of $\leq 6$ episodes or $> 6$ episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.	
Comparison groups	BOTOX 50 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1567
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	34.11

Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.536
upper limit	81.76
Variability estimate	Standard error of the mean
Dispersion value	23.722

## Secondary: Change From Study Baseline in Pediatric Urinary Incontinence Quality of Life Total Score (PinQ)

End point title	Change From Study Baseline in Pediatric Urinary Incontinence Quality of Life Total Score (PinQ)
-----------------	---

End point description:

The PinQ is a 20-item questionnaire that asks about the subject's incontinence and its consequences in daily life and relationships. Items are answered on a Likert-type scale of 0 (no) to 4 (all of the time) and a total sum score is calculated (from 0 to 80), with higher scores indicating lower health-related quality of life. A negative change from Baseline indicates improvement.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 Prior to Treatment to Week 12 in Treatment Cycle 1

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[16]</sup>	17 <sup>[17]</sup>	20 <sup>[18]</sup>	
Units: units on a scale				
least squares mean (standard error)	-6.96 (± 2.841)	-5.11 (± 3.243)	-8.28 (± 2.979)	

Notes:

[16] - Subjects with analysis values at both baseline and Week 12

[17] - Subjects with analysis values at both baseline and Week 12

[18] - Subjects with analysis values at both baseline and Week 12

## Statistical analyses

Statistical analysis title	Treatment Difference of 100 U versus 25 U
----------------------------	---

Statistical analysis description:

Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of ≤ 6 episodes or > 6 episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.

Comparison groups	BOTOX 100 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
-------------------	--

Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7481
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.553
upper limit	6.909
Variability estimate	Standard error of the mean
Dispersion value	4.091

<b>Statistical analysis title</b>	Treatment Difference of 50 U versus 25 U
-----------------------------------	--

Statistical analysis description:

Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of  $\leq 6$  episodes or  $> 6$  episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.

Comparison groups	BOTOX 25 U (BOTOX-Treated Population) v BOTOX 50 U (BOTOX-Treated Population)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6691
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	1.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.799
upper limit	10.498
Variability estimate	Standard error of the mean
Dispersion value	4.299

**Secondary: Change From Study Baseline in PinQ item 'I am worried that people might think my clothes smell like pee'**

End point title	Change From Study Baseline in PinQ item 'I am worried that people might think my clothes smell like pee'
-----------------	--

End point description:

The Pediatric Urinary Incontinence Quality of (PinQ) is a 20-item questionnaire that asks about the subject's incontinence and its consequences in daily life and relationships. Items are answered on a Likert-type scale of 0 (no) to 4 (all of the time), with higher scores indicating lower health-related quality of life. A negative change from Baseline indicates improvement.

End point type	Secondary
End point timeframe:	
From Day 1 Prior to Treatment to Week 12 in Treatment Cycle 1	

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[19]</sup>	17 <sup>[20]</sup>	20 <sup>[21]</sup>	
Units: units on a scale				
least squares mean (standard error)	-0.06 (± 0.238)	-0.37 (± 0.273)	-0.09 (± 0.251)	

Notes:

[19] - Subjects with analysis values at both baseline and Week 12

[20] - Subjects with analysis values at both baseline and Week 12

[21] - Subjects with analysis values at both baseline and Week 12

## Statistical analyses

<b>Statistical analysis title</b>	Treatment Difference of 100 U versus 25 U
-----------------------------------	---

Statistical analysis description:

Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of ≤ 6 episodes or > 6 episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.

Comparison groups	BOTOX 100 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9297
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.721
upper limit	0.661
Variability estimate	Standard error of the mean
Dispersion value	0.343

<b>Statistical analysis title</b>	Treatment Difference of 50 U versus 25 U
-----------------------------------	--

Statistical analysis description:

Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of ≤ 6 episodes or > 6 episodes over

the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.

Comparison groups	BOTOX 25 U (BOTOX-Treated Population) v BOTOX 50 U (BOTOX-Treated Population)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3976
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.022
upper limit	0.413
Variability estimate	Standard error of the mean
Dispersion value	0.357

### Secondary: Change From Study Baseline in PinQ item 'My bladder problem makes me feel bad about myself'

End point title	Change From Study Baseline in PinQ item 'My bladder problem makes me feel bad about myself'
End point description:	
The Pediatric Urinary Incontinence Quality of (PinQ) is a 20-item questionnaire that asks about the subject's incontinence and its consequences in daily life and relationships. Items are answered on a Likert-type scale of 0 (no) to 4 (all of the time), with higher scores indicating lower health-related quality of life. A negative change from Baseline indicates improvement.	
End point type	Secondary
End point timeframe:	
From Day 1 Prior to Treatment to Week 12 in Treatment Cycle 1	

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[22]</sup>	17 <sup>[23]</sup>	20 <sup>[24]</sup>	
Units: units on a scale				
least squares mean (standard error)	-0.54 (± 0.209)	-0.15 (± 0.238)	-0.24 (± 0.220)	

Notes:

[22] - Subjects with analysis values at both baseline and Week 12

[23] - Subjects with analysis values at both baseline and Week 12

[24] - Subjects with analysis values at both baseline and Week 12

### Statistical analyses

<b>Statistical analysis title</b>	Treatment Difference of 100 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of $\leq 6$ episodes or $> 6$ episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.	
Comparison groups	BOTOX 100 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3309
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.311
upper limit	0.904
Variability estimate	Standard error of the mean
Dispersion value	0.302

<b>Statistical analysis title</b>	Treatment Difference of 50 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of $\leq 6$ episodes or $> 6$ episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.	
Comparison groups	BOTOX 25 U (BOTOX-Treated Population) v BOTOX 50 U (BOTOX-Treated Population)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2235
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.39
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.245
upper limit	1.024
Variability estimate	Standard error of the mean
Dispersion value	0.315



## Secondary: Change From Study Baseline in PinQ item 'I miss out on being with friends because of my bladder problems'

End point title	Change From Study Baseline in PinQ item 'I miss out on being with friends because of my bladder problems'
-----------------	---

### End point description:

The Pediatric Urinary Incontinence Quality of (PinQ) is a 20-item questionnaire that asks about the subject's incontinence and its consequences in daily life and relationships. Items are answered on a Likert-type scale of 0 (no) to 4 (all of the time), with higher scores indicating lower health-related quality of life. A negative change from Baseline indicates improvement.

End point type	Secondary
----------------	-----------

### End point timeframe:

From Day 1 Prior to Treatment to Week 12 in Treatment Cycle 1

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18 <sup>[25]</sup>	17 <sup>[26]</sup>	20 <sup>[27]</sup>	
Units: units on a scale				
least squares mean (standard error)	-0.39 (± 0.193)	-0.24 (± 0.218)	-0.27 (± 0.201)	

### Notes:

[25] - Subjects with analysis values at both baseline and Week 12

[26] - Subjects with analysis values at both baseline and Week 12

[27] - Subjects with analysis values at both baseline and Week 12

## Statistical analyses

Statistical analysis title	Treatment Difference of 100 U versus 25 U
----------------------------	---

### Statistical analysis description:

Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of ≤ 6 episodes or > 6 episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.

Comparison groups	BOTOX 100 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6689
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.434
upper limit	0.67
Variability estimate	Standard error of the mean
Dispersion value	0.274

<b>Statistical analysis title</b>	Treatment Difference of 50 U versus 25 U
-----------------------------------	--

Statistical analysis description:

Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using an ANCOVA model with study baseline value as covariate, and treatment group and stratification (baseline daytime urinary urgency incontinence episodes [a total of  $\leq 6$  episodes or  $> 6$  episodes over the 2-day diary collection period]) as factors. A hierarchical analysis strategy to adjust for multiplicity was not implemented.

Comparison groups	BOTOX 25 U (BOTOX-Treated Population) v BOTOX 50 U (BOTOX-Treated Population)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6076
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.431
upper limit	0.729
Variability estimate	Standard error of the mean
Dispersion value	0.288

### Secondary: Percentage of Participants with a Positive Treatment Response in the Modified Treatment Benefit Scale

End point title	Percentage of Participants with a Positive Treatment Response in the Modified Treatment Benefit Scale
-----------------	---

End point description:

The Modified Treatment Benefit Scale (Modified TBS) is a single-item scale designed to assess the change in the subject's overactive bladder (OAB) condition following treatment. The subject's current condition (urinary problems, urinary incontinence) is compared to their condition prior to receipt of any study treatment by selection of "greatly improved", "improved", "not changed" or "worsened". Subjects who selected "greatly improved" or "improved" were considered to have a positive treatment response.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 12 in Treatment Cycle 1

<b>End point values</b>	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17 <sup>[28]</sup>	17 <sup>[29]</sup>	19 <sup>[30]</sup>	
Units: percentage of participants				
number (confidence interval 95%)	52.9 (27.81 to	70.6 (44.04 to	68.4 (43.45 to	

Notes:

[28] - Subjects with non-missing values at Week 12.

[29] - Subjects with non-missing values at Week 12.

[30] - Subjects with non-missing values at Week 12.

## Statistical analyses

Statistical analysis title	Treatment Difference of 100 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 100 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using the Cochran-Mantel-Haenszel (CMH) method stratified by baseline daytime urinary urgency incontinence episodes (a total of $\leq 6$ episodes or $> 6$ episodes over the 2-day diary collection period).	
Comparison groups	BOTOX 100 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	36
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6092
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference %
Point estimate	15.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.94
upper limit	46.19

Statistical analysis title	Treatment Difference of 50 U versus 25 U
Statistical analysis description:	
Pairwise comparisons of 50 U versus 25 U of BOTOX up to Week 12 in Treatment Cycle 1 was evaluated using the Cochran-Mantel-Haenszel (CMH) method stratified by baseline daytime urinary urgency incontinence episodes (a total of $\leq 6$ episodes or $> 6$ episodes over the 2-day diary collection period).	
Comparison groups	BOTOX 50 U (BOTOX-Treated Population) v BOTOX 25 U (BOTOX-Treated Population)
Number of subjects included in analysis	34
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4824
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference %
Point estimate	17.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.2
upper limit	48.9

---

**Secondary: Time to Subject's First Request for Retreatment**

---

End point title	Time to Subject's First Request for Retreatment
-----------------	---

End point description:

The time from the day of BOTOX treatment to the request for the subsequent treatment was estimated using a Kaplan-Meier survival method for each treatment group. Subjects who did not request retreatment were treated as censored at the time of their last study visit or study exit.

End point type	Secondary
----------------	-----------

End point timeframe:

From the day of BOTOX treatment in Treatment Cycle 1 to the request for subsequent treatment

---

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17 <sup>[31]</sup>	14 <sup>[32]</sup>	17 <sup>[33]</sup>	
Units: weeks				
median (confidence interval 95%)	16.6 (12.71 to 25.29)	17.6 (11.29 to 38.57)	21.3 (12.86 to 30.14)	

Notes:

[31] - BOTOX-treated subjects who requested retreatment

[32] - BOTOX-treated subjects who requested retreatment

[33] - BOTOX-treated subjects who requested retreatment

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Time to Subject's Qualification for Retreatment**

---

End point title	Time to Subject's Qualification for Retreatment
-----------------	---

End point description:

The time from the day of BOTOX treatment to the qualification for retreatment was estimated using a Kaplan-Meier survival method for each treatment group. Subjects who did not qualify for retreatment were treated as censored at the time of their last study visit or study exit.

End point type	Secondary
----------------	-----------

End point timeframe:

From the day of BOTOX treatment in Treatment Cycle 1 to the qualification for retreatment

---

End point values	BOTOX 25 U (BOTOX-Treated Population)	BOTOX 50 U (BOTOX-Treated Population)	BOTOX 100 U (BOTOX-Treated Population)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16 <sup>[34]</sup>	14 <sup>[35]</sup>	17 <sup>[36]</sup>	
Units: weeks				
median (confidence interval 95%)	22.5 (13.57 to	18.1 (12.29 to	24.1 (12.86 to	

36.29)

52.57)

41.57)

Notes:

[34] - BOTOX-treated subjects who qualified for retreatment

[35] - BOTOX-treated subjects who qualified for retreatment

[36] - BOTOX-treated subjects who qualified for retreatment

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Number of Participants With Treatment Emergent Adverse Events

End point title	Number of Participants With Treatment Emergent Adverse Events
-----------------	---

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

From the first dose of study drug until the last dose, up to 147 weeks

End point values	BOTOX-treated population			
Subject group type	Subject analysis set			
Number of subjects analysed				
Units: number of participants	48			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All-cause mortality is reported from enrollment to the end of study; median time on follow-up was up to 724 days. TEAEs/SAEs were collected from the first dose of study drug until the last dose, up to 147 weeks.

Adverse event reporting additional description:

For safety analyses, participants were assigned to a treatment group based on the treatment actually received, regardless of the treatment randomized.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

### Reporting groups

Reporting group title	25 U BOTOX All
-----------------------	----------------

Reporting group description:

All participants who received 25 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	100 U BOTOX All
-----------------------	-----------------

Reporting group description:

All participants who received 100 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	50 U BOTOX All
-----------------------	----------------

Reporting group description:

All participants who received 50 U BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	25 U BOTOX Cycle 1
-----------------------	--------------------

Reporting group description:

Participants who received 25 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 1, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	50 U BOTOX Cycle 1
-----------------------	--------------------

Reporting group description:

Participants who received 50 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 1, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	25 U BOTOX Cycle 2
-----------------------	--------------------

Reporting group description:

Participants who received 25 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 2, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	All BOTOX Cycle 1
-----------------------	-------------------

Reporting group description:

All BOTOX-treated participants in Treatment Cycle 1

Reporting group title	100 U BOTOX Cycle 1
-----------------------	---------------------

Reporting group description:

Participants who received 100 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 1, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	50 U BOTOX Cycle 2
-----------------------	--------------------

Reporting group description:

Participants who received 50 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 2, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	100 U BOTOX Cycle 2
-----------------------	---------------------

Reporting group description:

Participants who received 100 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 2, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.

Reporting group title	All BOTOX Cycle 2
Reporting group description: All BOTOX-treated participants in Treatment Cycle 2	
Reporting group title	25 U BOTOX Cycle 3
Reporting group description: Participants who received 25 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 3, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.	
Reporting group title	50 U BOTOX Cycle 3
Reporting group description: Participants who received 50 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 3, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.	
Reporting group title	100 U BOTOX Cycle 3
Reporting group description: Participants who received 100 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 3, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.	
Reporting group title	50 U BOTOX Cycle 4
Reporting group description: Participants who received 50 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 4, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone	
Reporting group title	All BOTOX Cycle 3
Reporting group description: All BOTOX-treated participants in Treatment Cycle 3	
Reporting group title	100 U BOTOX Cycle 4
Reporting group description: Participants who received 100 U BOTOX (not to exceed 6 U/kg) in Treatment Cycle 4, administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone.	
Reporting group title	All BOTOX Cycle 4
Reporting group description: All BOTOX-treated participants in Treatment Cycle 4	

<b>Serious adverse events</b>	25 U BOTOX All	100 U BOTOX All	50 U BOTOX All
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 18 (5.56%)	1 / 33 (3.03%)	0 / 29 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
PALLOR			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
MALAISE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Social circumstances SOCIAL PROBLEM subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 18 (5.56%) 0 / 1 0 / 0	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 29 (0.00%) 0 / 0 0 / 0
Gastrointestinal disorders ABDOMINAL PAIN subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 18 (5.56%) 0 / 1 0 / 0	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 29 (0.00%) 0 / 0 0 / 0
Psychiatric disorders ANXIETY DISORDER subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 18 (0.00%) 0 / 0 0 / 0	1 / 33 (3.03%) 0 / 1 0 / 0	0 / 29 (0.00%) 0 / 0 0 / 0
Musculoskeletal and connective tissue disorders BACK PAIN subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 18 (5.56%) 0 / 1 0 / 0	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 29 (0.00%) 0 / 0 0 / 0

<b>Serious adverse events</b>	25 U BOTOX Cycle 1	50 U BOTOX Cycle 1	25 U BOTOX Cycle 2
Total subjects affected by serious adverse events subjects affected / exposed number of deaths (all causes) number of deaths resulting from adverse events	1 / 18 (5.56%) 0 0	0 / 17 (0.00%) 0 0	0 / 1 (0.00%) 0 0
Vascular disorders PALLOR subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 18 (0.00%) 0 / 0 0 / 0	0 / 17 (0.00%) 0 / 0 0 / 0	0 / 1 (0.00%) 0 / 0 0 / 0
General disorders and administration site conditions MALAISE subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 18 (0.00%) 0 / 0 0 / 0	0 / 17 (0.00%) 0 / 0 0 / 0	0 / 1 (0.00%) 0 / 0 0 / 0



Social circumstances SOCIAL PROBLEM subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 18 (5.56%) 0 / 1 0 / 0	0 / 17 (0.00%) 0 / 0 0 / 0	0 / 1 (0.00%) 0 / 0 0 / 0
Gastrointestinal disorders ABDOMINAL PAIN subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 18 (5.56%) 0 / 1 0 / 0	0 / 17 (0.00%) 0 / 0 0 / 0	0 / 1 (0.00%) 0 / 0 0 / 0
Psychiatric disorders ANXIETY DISORDER subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 18 (0.00%) 0 / 0 0 / 0	0 / 17 (0.00%) 0 / 0 0 / 0	0 / 1 (0.00%) 0 / 0 0 / 0
Musculoskeletal and connective tissue disorders BACK PAIN subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 18 (5.56%) 0 / 1 0 / 0	0 / 17 (0.00%) 0 / 0 0 / 0	0 / 1 (0.00%) 0 / 0 0 / 0
<b>Serious adverse events</b>	All BOTOX Cycle 1	100 U BOTOX Cycle 1	50 U BOTOX Cycle 2
Total subjects affected by serious adverse events subjects affected / exposed number of deaths (all causes) number of deaths resulting from adverse events	1 / 55 (1.82%) 0 0	0 / 20 (0.00%) 0 0	0 / 17 (0.00%) 0 0
Vascular disorders PALLOR subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 55 (0.00%) 0 / 0 0 / 0	0 / 20 (0.00%) 0 / 0 0 / 0	0 / 17 (0.00%) 0 / 0 0 / 0
General disorders and administration site conditions MALAISE			

subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances SOCIAL PROBLEM			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders ABDOMINAL PAIN			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders ANXIETY DISORDER			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders BACK PAIN			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	100 U BOTOX Cycle 2	All BOTOX Cycle 2	25 U BOTOX Cycle 3
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 28 (3.57%)	1 / 46 (2.17%)	0 / 2 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders PALLOR			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

MALAISE			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
SOCIAL PROBLEM			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
ANXIETY DISORDER			
subjects affected / exposed	1 / 28 (3.57%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
BACK PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Serious adverse events</b>	<b>50 U BOTOX Cycle 3</b>	<b>100 U BOTOX Cycle 3</b>	<b>50 U BOTOX Cycle 4</b>
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
PALLOR			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration			

site conditions MALAISE			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances SOCIAL PROBLEM			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders ABDOMINAL PAIN			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders ANXIETY DISORDER			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders BACK PAIN			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	All BOTOX Cycle 3	100 U BOTOX Cycle 4	All BOTOX Cycle 4
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders PALLOR			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions MALAISE subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 22 (4.55%) 0 / 1 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0
Social circumstances SOCIAL PROBLEM subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 22 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0
Gastrointestinal disorders ABDOMINAL PAIN subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 22 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0
Psychiatric disorders ANXIETY DISORDER subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 22 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0
Musculoskeletal and connective tissue disorders BACK PAIN subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 22 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	25 U BOTOX All	100 U BOTOX All	50 U BOTOX All
Total subjects affected by non-serious adverse events subjects affected / exposed	12 / 18 (66.67%)	24 / 33 (72.73%)	23 / 29 (79.31%)
Vascular disorders FLUSHING subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 33 (0.00%) 0	1 / 29 (3.45%) 1

HAEMATOMA			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
RAYNAUD'S PHENOMENON			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
CHRONIC FATIGUE SYNDROME			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
FATIGUE			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
ILLNESS			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
MALAISE			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
PAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
PYREXIA			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	1 / 29 (3.45%)
occurrences (all)	0	1	1
Reproductive system and breast disorders			
DYSMENORRHOEA			
subjects affected / exposed	0 / 18 (0.00%)	2 / 33 (6.06%)	0 / 29 (0.00%)
occurrences (all)	0	2	0
GENITAL PAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
HAEMORRHAGIC OVARIAN CYST			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
HEAVY MENSTRUAL BLEEDING subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
OEDEMA GENITAL subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
VAGINAL HAEMORRHAGE subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
VULVOVAGINAL DISCOMFORT subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
COUGH subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	2 / 33 (6.06%) 2	0 / 29 (0.00%) 0
NASAL CONGESTION subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
OROPHARYNGEAL PAIN subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	2 / 33 (6.06%) 2	1 / 29 (3.45%) 3
Psychiatric disorders			
ANOREXIA NERVOSA subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 33 (0.00%) 0	1 / 29 (3.45%) 1
ANXIETY subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Investigations			
BLOOD ALKALINE PHOSPHATASE INCREASED subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
BLOOD BILIRUBIN INCREASED			

subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
BLOOD URINE PRESENT			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
CRYSTAL URINE PRESENT			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
CYTOMEGALOVIRUS TEST POSITIVE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
EPSTEIN-BARR VIRUS TEST POSITIVE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
RED BLOOD CELLS URINE POSITIVE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
RESIDUAL URINE VOLUME			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
URINE LEUKOCYTE ESTERASE POSITIVE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
ANIMAL BITE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
ANIMAL SCRATCH			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
CLAVICLE FRACTURE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
CONTUSION			



subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
FALL			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	2	0	1
JOINT INJURY			
subjects affected / exposed	0 / 18 (0.00%)	2 / 33 (6.06%)	0 / 29 (0.00%)
occurrences (all)	0	2	0
LIGAMENT SPRAIN			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
POST PROCEDURAL DISCOMFORT			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
PROCEDURAL PAIN			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
TENDON INJURY			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
TACHYCARDIA			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
HEADACHE			
subjects affected / exposed	0 / 18 (0.00%)	4 / 33 (12.12%)	2 / 29 (6.90%)
occurrences (all)	0	4	2
MIGRAINE			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Blood and lymphatic system disorders ANAEMIA subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Ear and labyrinth disorders HYPERACUSIS subjects affected / exposed occurrences (all)  MISOPHONIA subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0  0 / 18 (0.00%) 0	0 / 33 (0.00%) 0  0 / 33 (0.00%) 0	0 / 29 (0.00%) 0  0 / 29 (0.00%) 0
Eye disorders EYE PAIN subjects affected / exposed occurrences (all)  OCULAR HYPERAEMIA subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0  0 / 18 (0.00%) 0	0 / 33 (0.00%) 0  0 / 33 (0.00%) 0	1 / 29 (3.45%) 1  1 / 29 (3.45%) 1
Gastrointestinal disorders ABDOMINAL DISTENSION subjects affected / exposed occurrences (all)  ABDOMINAL PAIN subjects affected / exposed occurrences (all)  ABDOMINAL PAIN LOWER subjects affected / exposed occurrences (all)  ABDOMINAL PAIN UPPER subjects affected / exposed occurrences (all)  CONSTIPATION subjects affected / exposed occurrences (all)  DIARRHOEA	0 / 18 (0.00%) 0  2 / 18 (11.11%) 2  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0	1 / 33 (3.03%) 1  0 / 33 (0.00%) 0  1 / 33 (3.03%) 1  1 / 33 (3.03%) 1  0 / 33 (0.00%) 0	0 / 29 (0.00%) 0  2 / 29 (6.90%) 2  1 / 29 (3.45%) 1  0 / 29 (0.00%) 0  1 / 29 (3.45%) 1

subjects affected / exposed	1 / 18 (5.56%)	1 / 33 (3.03%)	1 / 29 (3.45%)
occurrences (all)	1	1	1
DYSPEPSIA			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
IRRITABLE BOWEL SYNDROME			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
NAUSEA			
subjects affected / exposed	1 / 18 (5.56%)	1 / 33 (3.03%)	1 / 29 (3.45%)
occurrences (all)	1	1	1
TOOTHACHE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
VOMITING			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	3 / 29 (10.34%)
occurrences (all)	0	0	3
Skin and subcutaneous tissue disorders			
ACNE			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	1 / 29 (3.45%)
occurrences (all)	0	1	1
ALOPECIA			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
DERMATITIS CONTACT			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
ECZEMA			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
NAIL BED INFLAMMATION			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	2
RASH			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1

URTICARIA subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
Renal and urinary disorders			
BLADDER DISCOMFORT subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
BLADDER SPASM subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
DYSURIA subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2	3 / 33 (9.09%) 3	5 / 29 (17.24%) 5
HAEMATURIA subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 3	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
LEUKOCYTURIA subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 33 (0.00%) 0	2 / 29 (6.90%) 3
POLAKIURIA subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 33 (0.00%) 0	1 / 29 (3.45%) 1
PROTEINURIA subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
URETHRAL PAIN subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	2 / 33 (6.06%) 2	0 / 29 (0.00%) 0
URINARY INCONTINENCE subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 33 (0.00%) 0	1 / 29 (3.45%) 1
Musculoskeletal and connective tissue disorders			
ARTHRALGIA subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
BACK PAIN			

subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	2	0	1
FLANK PAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
JOINT SWELLING			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
MUSCLE SPASMS			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	2
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	1 / 29 (3.45%)
occurrences (all)	0	1	1
SACRAL PAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
SPONDYLOLISTHESIS			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
BACTERIURIA			
subjects affected / exposed	1 / 18 (5.56%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	1	1	0
EAR INFECTION			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
FUNGAL SKIN INFECTION			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

GASTROENTERITIS			
subjects affected / exposed	0 / 18 (0.00%)	2 / 33 (6.06%)	2 / 29 (6.90%)
occurrences (all)	0	2	2
GASTROENTERITIS VIRAL			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
INFLUENZA			
subjects affected / exposed	0 / 18 (0.00%)	2 / 33 (6.06%)	1 / 29 (3.45%)
occurrences (all)	0	2	1
LARYNGITIS			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
NASOPHARYNGITIS			
subjects affected / exposed	1 / 18 (5.56%)	6 / 33 (18.18%)	2 / 29 (6.90%)
occurrences (all)	1	8	4
PARONYCHIA			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
PHARYNGITIS			
subjects affected / exposed	1 / 18 (5.56%)	1 / 33 (3.03%)	1 / 29 (3.45%)
occurrences (all)	1	1	3
RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
RHINOVIRUS INFECTION			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
SINUSITIS			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
TONSILLITIS			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	2 / 29 (6.90%)
occurrences (all)	0	1	4
TRACHEOBRONCHITIS			

subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 18 (5.56%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	1	1	0
URINARY TRACT INFECTION			
subjects affected / exposed	2 / 18 (11.11%)	6 / 33 (18.18%)	6 / 29 (20.69%)
occurrences (all)	3	9	11
VIRAL INFECTION			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL CANDIDIASIS			
subjects affected / exposed	1 / 18 (5.56%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
ABNORMAL WEIGHT GAIN			
subjects affected / exposed	0 / 18 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
VITAMIN D DEFICIENCY			
subjects affected / exposed	0 / 18 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1

Non-serious adverse events	25 U BOTOX Cycle 1	50 U BOTOX Cycle 1	25 U BOTOX Cycle 2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 18 (66.67%)	12 / 17 (70.59%)	1 / 1 (100.00%)
Vascular disorders			
FLUSHING			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
HAEMATOMA			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
RAYNAUD'S PHENOMENON			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			

CHRONIC FATIGUE SYNDROME			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
FATIGUE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ILLNESS			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
MALAISE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PAIN			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PYREXIA			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
DYSMENORRHOEA			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
GENITAL PAIN			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
HAEMORRHAGIC OVARIAN CYST			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
HEAVY MENSTRUAL BLEEDING			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
OEDEMA GENITAL			



subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
VAGINAL HAEMORRHAGE			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
VULVOVAGINAL DISCOMFORT			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
NASAL CONGESTION			
subjects affected / exposed	2 / 18 (11.11%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
OROPHARYNGEAL PAIN			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	1	3	0
Psychiatric disorders			
ANOREXIA NERVOSA			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
ANXIETY			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Investigations			
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BLOOD URINE PRESENT			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
CRYSTAL URINE PRESENT			

subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CYTOMEGALOVIRUS TEST POSITIVE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
EPSTEIN-BARR VIRUS TEST POSITIVE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELLS URINE POSITIVE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
RESIDUAL URINE VOLUME			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
URINE LEUKOCYTE ESTERASE POSITIVE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
ANIMAL BITE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ANIMAL SCRATCH			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CLAVICLE FRACTURE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CONTUSION			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
FALL			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
JOINT INJURY			

subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
LIGAMENT SPRAIN			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
POST PROCEDURAL DISCOMFORT			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PROCEDURAL PAIN			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
TENDON INJURY			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
TACHYCARDIA			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
HEADACHE			
subjects affected / exposed	0 / 18 (0.00%)	2 / 17 (11.76%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
MIGRAINE			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			

HYPERACUSIS			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MISOPHONIA			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
EYE PAIN			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
OCULAR HYPERAEMIA			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
ABDOMINAL DISTENSION			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN			
subjects affected / exposed	2 / 18 (11.11%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	2	1	0
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
DIARRHOEA			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
DYSPEPSIA			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
IRRITABLE BOWEL SYNDROME			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
NAUSEA subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
TOOTHACHE subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
VOMITING subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
Skin and subcutaneous tissue disorders			
ACNE subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
ALOPECIA subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
DERMATITIS CONTACT subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
ECZEMA subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	0 / 1 (0.00%) 0
NAIL BED INFLAMMATION subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
RASH subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
URTICARIA subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	0 / 1 (0.00%) 0
Renal and urinary disorders			
BLADDER DISCOMFORT			

subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BLADDER SPASM			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
DYSURIA			
subjects affected / exposed	2 / 18 (11.11%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	2	1	0
HAEMATURIA			
subjects affected / exposed	2 / 18 (11.11%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0
LEUKOCYTURIA			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
POLLAKIURIA			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
PROTEINURIA			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
URETHRAL PAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
URINARY INCONTINENCE			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BACK PAIN			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	2	1	0
FLANK PAIN			

subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
JOINT SWELLING			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
SACRAL PAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
SPONDYLOLISTHESIS			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
BACTERIURIA			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
EAR INFECTION			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
FUNGAL SKIN INFECTION			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0

GASTROENTERITIS VIRAL			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
INFLUENZA			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
LARYNGITIS			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
NASOPHARYNGITIS			
subjects affected / exposed	1 / 18 (5.56%)	2 / 17 (11.76%)	0 / 1 (0.00%)
occurrences (all)	1	4	0
PARONYCHIA			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PHARYNGITIS			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	1	3	0
RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
RHINOVIRUS INFECTION			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
SINUSITIS			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
TONSILLITIS			
subjects affected / exposed	0 / 18 (0.00%)	2 / 17 (11.76%)	0 / 1 (0.00%)
occurrences (all)	0	4	0
TRACHEOBRONCHITIS			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
UPPER RESPIRATORY TRACT INFECTION			



subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
URINARY TRACT INFECTION			
subjects affected / exposed	2 / 18 (11.11%)	2 / 17 (11.76%)	0 / 1 (0.00%)
occurrences (all)	3	4	0
VIRAL INFECTION			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL CANDIDIASIS			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
ABNORMAL WEIGHT GAIN			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
VITAMIN D DEFICIENCY			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	All BOTOX Cycle 1	100 U BOTOX Cycle 1	50 U BOTOX Cycle 2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	38 / 55 (69.09%)	14 / 20 (70.00%)	13 / 17 (76.47%)
Vascular disorders			
FLUSHING			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
HAEMATOMA			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
RAYNAUD'S PHENOMENON			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
CHRONIC FATIGUE SYNDROME			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0

FATIGUE			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
ILLNESS			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
MALAISE			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
PAIN			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
PERIPHERAL SWELLING			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
PYREXIA			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	1 / 17 (5.88%)
occurrences (all)	1	1	1
Reproductive system and breast disorders			
DYSMENORRHOEA			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
GENITAL PAIN			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
HAEMORRHAGIC OVARIAN CYST			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
HEAVY MENSTRUAL BLEEDING			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
OEDEMA GENITAL			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
VAGINAL HAEMORRHAGE			

subjects affected / exposed occurrences (all)	1 / 55 (1.82%) 1	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0
VULVOVAGINAL DISCOMFORT subjects affected / exposed occurrences (all)	1 / 55 (1.82%) 1	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)	0 / 55 (0.00%) 0	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0
NASAL CONGESTION subjects affected / exposed occurrences (all)	2 / 55 (3.64%) 2	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0
OROPHARYNGEAL PAIN subjects affected / exposed occurrences (all)	4 / 55 (7.27%) 6	2 / 20 (10.00%) 2	0 / 17 (0.00%) 0
Psychiatric disorders ANOREXIA NERVOSA subjects affected / exposed occurrences (all)	1 / 55 (1.82%) 1	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0
ANXIETY subjects affected / exposed occurrences (all)	1 / 55 (1.82%) 1	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1
Investigations BLOOD ALKALINE PHOSPHATASE INCREASED subjects affected / exposed occurrences (all)	1 / 55 (1.82%) 1	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0
BLOOD BILIRUBIN INCREASED subjects affected / exposed occurrences (all)	1 / 55 (1.82%) 1	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0
BLOOD URINE PRESENT subjects affected / exposed occurrences (all)	1 / 55 (1.82%) 1	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0
CRYSTAL URINE PRESENT subjects affected / exposed occurrences (all)	1 / 55 (1.82%) 1	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0
CYTOMEGALOVIRUS TEST POSITIVE			

subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
EPSTEIN-BARR VIRUS TEST POSITIVE			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
RED BLOOD CELLS URINE POSITIVE			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
RESIDUAL URINE VOLUME			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
URINE LEUKOCYTE ESTERASE POSITIVE			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
ANIMAL BITE			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
ANIMAL SCRATCH			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
CLAVICLE FRACTURE			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
CONTUSION			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
FALL			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	2	0	1
JOINT INJURY			
subjects affected / exposed	2 / 55 (3.64%)	2 / 20 (10.00%)	0 / 17 (0.00%)
occurrences (all)	2	2	0
LIGAMENT SPRAIN			

subjects affected / exposed	2 / 55 (3.64%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	2	0	0
POST PROCEDURAL DISCOMFORT			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
PROCEDURAL PAIN			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
TENDON INJURY			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Cardiac disorders			
TACHYCARDIA			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	2	0	0
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
HEADACHE			
subjects affected / exposed	5 / 55 (9.09%)	3 / 20 (15.00%)	0 / 17 (0.00%)
occurrences (all)	5	3	0
MIGRAINE			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
HYPERACUSIS			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
MISOPHONIA			

subjects affected / exposed occurrences (all)	0 / 55 (0.00%) 0	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1
Eye disorders			
EYE PAIN			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
OCULAR HYPERAEMIA			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
ABDOMINAL DISTENSION			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
ABDOMINAL PAIN			
subjects affected / exposed	3 / 55 (5.45%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	3	0	1
ABDOMINAL PAIN LOWER			
subjects affected / exposed	2 / 55 (3.64%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	2	1	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
CONSTIPATION			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
DIARRHOEA			
subjects affected / exposed	2 / 55 (3.64%)	1 / 20 (5.00%)	1 / 17 (5.88%)
occurrences (all)	2	1	1
DYSPEPSIA			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
IRRITABLE BOWEL SYNDROME			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
NAUSEA			

subjects affected / exposed	2 / 55 (3.64%)	1 / 20 (5.00%)	1 / 17 (5.88%)
occurrences (all)	2	1	1
TOOTHACHE			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
VOMITING			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	3 / 17 (17.65%)
occurrences (all)	0	0	3
Skin and subcutaneous tissue disorders			
ACNE			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	1 / 17 (5.88%)
occurrences (all)	1	1	1
ALOPECIA			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
DERMATITIS CONTACT			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
ECZEMA			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
NAIL BED INFLAMMATION			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	2
RASH			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
URTICARIA			
subjects affected / exposed	2 / 55 (3.64%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	2	1	0
Renal and urinary disorders			
BLADDER DISCOMFORT			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
BLADDER SPASM			

subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
DYSURIA			
subjects affected / exposed	5 / 55 (9.09%)	2 / 20 (10.00%)	4 / 17 (23.53%)
occurrences (all)	5	2	4
HAEMATURIA			
subjects affected / exposed	2 / 55 (3.64%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	3	0	0
LEUKOCYTURIA			
subjects affected / exposed	2 / 55 (3.64%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	2	0	2
POLLAKIURIA			
subjects affected / exposed	2 / 55 (3.64%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	2	0	0
PROTEINURIA			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
URETHRAL PAIN			
subjects affected / exposed	2 / 55 (3.64%)	2 / 20 (10.00%)	0 / 17 (0.00%)
occurrences (all)	2	2	0
URINARY INCONTINENCE			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
BACK PAIN			
subjects affected / exposed	2 / 55 (3.64%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	3	0	0
FLANK PAIN			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
JOINT SWELLING			



subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
<b>MUSCLE SPASMS</b>			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	2	0	0
<b>MUSCULOSKELETAL CHEST PAIN</b>			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
<b>MUSCULOSKELETAL PAIN</b>			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
<b>MYALGIA</b>			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
<b>SACRAL PAIN</b>			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
<b>SPONDYLOLISTHESIS</b>			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
<b>Infections and infestations</b>			
<b>BACTERIURIA</b>			
subjects affected / exposed	2 / 55 (3.64%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	2	1	0
<b>EAR INFECTION</b>			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	2 / 17 (11.76%)
occurrences (all)	1	0	2
<b>FUNGAL SKIN INFECTION</b>			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
<b>GASTROENTERITIS</b>			
subjects affected / exposed	2 / 55 (3.64%)	1 / 20 (5.00%)	1 / 17 (5.88%)
occurrences (all)	2	1	1
<b>GASTROENTERITIS VIRAL</b>			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0

INFLUENZA			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
LARYNGITIS			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
NASOPHARYNGITIS			
subjects affected / exposed	6 / 55 (10.91%)	3 / 20 (15.00%)	0 / 17 (0.00%)
occurrences (all)	9	4	0
PARONYCHIA			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
PHARYNGITIS			
subjects affected / exposed	2 / 55 (3.64%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	4	0	0
RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
RHINOVIRUS INFECTION			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
SINUSITIS			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
TONSILLITIS			
subjects affected / exposed	2 / 55 (3.64%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	4	0	0
TRACHEOBRONCHITIS			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
URINARY TRACT INFECTION			

subjects affected / exposed	6 / 55 (10.91%)	2 / 20 (10.00%)	4 / 17 (23.53%)
occurrences (all)	12	5	7
<b>VIRAL INFECTION</b>			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
<b>VULVOVAGINAL CANDIDIASIS</b>			
subjects affected / exposed	1 / 55 (1.82%)	0 / 20 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
<b>Metabolism and nutrition disorders</b>			
<b>ABNORMAL WEIGHT GAIN</b>			
subjects affected / exposed	1 / 55 (1.82%)	1 / 20 (5.00%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
<b>VITAMIN D DEFICIENCY</b>			
subjects affected / exposed	0 / 55 (0.00%)	0 / 20 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	100 U BOTOX Cycle 2	All BOTOX Cycle 2	25 U BOTOX Cycle 3
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 28 (64.29%)	32 / 46 (69.57%)	1 / 2 (50.00%)
<b>Vascular disorders</b>			
<b>FLUSHING</b>			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
<b>HAEMATOMA</b>			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
<b>RAYNAUD'S PHENOMENON</b>			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
<b>General disorders and administration site conditions</b>			
<b>CHRONIC FATIGUE SYNDROME</b>			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
<b>FATIGUE</b>			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

ILLNESS			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
MALAISE			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
PYREXIA			
subjects affected / exposed	1 / 28 (3.57%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
Reproductive system and breast disorders			
DYSMENORRHOEA			
subjects affected / exposed	2 / 28 (7.14%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	2	2	0
GENITAL PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
HAEMORRHAGIC OVARIAN CYST			
subjects affected / exposed	2 / 28 (7.14%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	2	2	0
HEAVY MENSTRUAL BLEEDING			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
OEDEMA GENITAL			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
VAGINAL HAEMORRHAGE			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL DISCOMFORT			

subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)	1 / 28 (3.57%) 1	1 / 46 (2.17%) 1	0 / 2 (0.00%) 0
NASAL CONGESTION subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
OROPHARYNGEAL PAIN subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
Psychiatric disorders ANOREXIA NERVOSA subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
ANXIETY subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	1 / 46 (2.17%) 1	0 / 2 (0.00%) 0
Investigations BLOOD ALKALINE PHOSPHATASE INCREASED subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
BLOOD BILIRUBIN INCREASED subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
BLOOD URINE PRESENT subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
CRYSTAL URINE PRESENT subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
CYTOMEGALOVIRUS TEST POSITIVE subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	1 / 46 (2.17%) 1	0 / 2 (0.00%) 0
EPSTEIN-BARR VIRUS TEST			

POSITIVE			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
RED BLOOD CELLS URINE POSITIVE			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
RESIDUAL URINE VOLUME			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
URINE LEUKOCYTE ESTERASE POSITIVE			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
ANIMAL BITE			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
ANIMAL SCRATCH			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
CLAVICLE FRACTURE			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
CONTUSION			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
FALL			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
JOINT INJURY			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
LIGAMENT SPRAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
POST PROCEDURAL DISCOMFORT			

subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
PROCEDURAL PAIN			
subjects affected / exposed	1 / 28 (3.57%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
TENDON INJURY			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
TACHYCARDIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	1 / 2 (50.00%)
occurrences (all)	0	1	2
HEADACHE			
subjects affected / exposed	3 / 28 (10.71%)	3 / 46 (6.52%)	0 / 2 (0.00%)
occurrences (all)	4	4	0
MIGRAINE			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Ear and labyrinth disorders			
HYPERACUSIS			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
MISOPHONIA			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Eye disorders			

EYE PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
OCULAR HYPERAEMIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISTENSION			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN			
subjects affected / exposed	2 / 28 (7.14%)	3 / 46 (6.52%)	0 / 2 (0.00%)
occurrences (all)	2	3	0
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
DIARRHOEA			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
DYSPEPSIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
IRRITABLE BOWEL SYNDROME			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
NAUSEA			
subjects affected / exposed	1 / 28 (3.57%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
TOOTHACHE			



subjects affected / exposed	1 / 28 (3.57%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
VOMITING			
subjects affected / exposed	0 / 28 (0.00%)	3 / 46 (6.52%)	0 / 2 (0.00%)
occurrences (all)	0	3	0
Skin and subcutaneous tissue disorders			
ACNE			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
ALOPECIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
DERMATITIS CONTACT			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
ECZEMA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
NAIL BED INFLAMMATION			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
RASH			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
URTICARIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
BLADDER DISCOMFORT			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
BLADDER SPASM			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
DYSURIA			

subjects affected / exposed	2 / 28 (7.14%)	6 / 46 (13.04%)	1 / 2 (50.00%)
occurrences (all)	2	6	1
HAEMATURIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
LEUKOCYTURIA			
subjects affected / exposed	1 / 28 (3.57%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	1	3	0
POLLAKIURIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
PROTEINURIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
URETHRAL PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
URINARY INCONTINENCE			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	2 / 28 (7.14%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	2	2	0
BACK PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
FLANK PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
JOINT SWELLING			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			

subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
subjects affected / exposed	1 / 28 (3.57%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
SACRAL PAIN			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
SPONDYLOLISTHESIS			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
BACTERIURIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
EAR INFECTION			
subjects affected / exposed	0 / 28 (0.00%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
FUNGAL SKIN INFECTION			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
GASTROENTERITIS			
subjects affected / exposed	1 / 28 (3.57%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
GASTROENTERITIS VIRAL			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
subjects affected / exposed	3 / 28 (10.71%)	3 / 46 (6.52%)	0 / 2 (0.00%)
occurrences (all)	3	3	0

LARYNGITIS			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
NASOPHARYNGITIS			
subjects affected / exposed	4 / 28 (14.29%)	4 / 46 (8.70%)	0 / 2 (0.00%)
occurrences (all)	6	6	0
PARONYCHIA			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
PHARYNGITIS			
subjects affected / exposed	1 / 28 (3.57%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 28 (0.00%)	1 / 46 (2.17%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
RHINOVIRUS INFECTION			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
SINUSITIS			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
TONSILLITIS			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
TRACHEOBRONCHITIS			
subjects affected / exposed	0 / 28 (0.00%)	0 / 46 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	2 / 28 (7.14%)	2 / 46 (4.35%)	0 / 2 (0.00%)
occurrences (all)	2	2	0
URINARY TRACT INFECTION			
subjects affected / exposed	9 / 28 (32.14%)	13 / 46 (28.26%)	0 / 2 (0.00%)
occurrences (all)	12	19	0
VIRAL INFECTION			

subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
VULVOVAGINAL CANDIDIASIS subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
Metabolism and nutrition disorders ABNORMAL WEIGHT GAIN subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	0 / 46 (0.00%) 0	0 / 2 (0.00%) 0
VITAMIN D DEFICIENCY subjects affected / exposed occurrences (all)	0 / 28 (0.00%) 0	1 / 46 (2.17%) 1	0 / 2 (0.00%) 0

<b>Non-serious adverse events</b>	50 U BOTOX Cycle 3	100 U BOTOX Cycle 3	50 U BOTOX Cycle 4
Total subjects affected by non-serious adverse events subjects affected / exposed	3 / 7 (42.86%)	8 / 13 (61.54%)	1 / 1 (100.00%)
Vascular disorders FLUSHING subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
HAEMATOMA subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
RAYNAUD'S PHENOMENON subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
General disorders and administration site conditions CHRONIC FATIGUE SYNDROME subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
FATIGUE subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
ILLNESS subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0

MALAISE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PAIN			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PYREXIA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
DYSMENORRHOEA			
subjects affected / exposed	1 / 7 (14.29%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	2	1	0
GENITAL PAIN			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
HAEMORRHAGIC OVARIAN CYST			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
HEAVY MENSTRUAL BLEEDING			
subjects affected / exposed	1 / 7 (14.29%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
OEDEMA GENITAL			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
VAGINAL HAEMORRHAGE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL DISCOMFORT			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			

COUGH			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
NASAL CONGESTION			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
ANOREXIA NERVOSA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ANXIETY			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Investigations			
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BLOOD URINE PRESENT			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CRYSTAL URINE PRESENT			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CYTOMEGALOVIRUS TEST POSITIVE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
EPSTEIN-BARR VIRUS TEST POSITIVE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELLS URINE POSITIVE			

subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
RESIDUAL URINE VOLUME			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
URINE LEUKOCYTE ESTERASE POSITIVE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
ANIMAL BITE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ANIMAL SCRATCH			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
CLAVICLE FRACTURE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CONTUSION			
subjects affected / exposed	1 / 7 (14.29%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
FALL			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
JOINT INJURY			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
LIGAMENT SPRAIN			
subjects affected / exposed	1 / 7 (14.29%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
POST PROCEDURAL DISCOMFORT			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
POST PROCEDURAL HAEMORRHAGE			



subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
PROCEDURAL PAIN subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
TENDON INJURY subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
Cardiac disorders TACHYCARDIA subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
Nervous system disorders DIZZINESS subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
HEADACHE subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	3 / 13 (23.08%) 4	0 / 1 (0.00%) 0
MIGRAINE subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
Blood and lymphatic system disorders ANAEMIA subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
Ear and labyrinth disorders HYPERACUSIS subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
MISOPHONIA subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
Eye disorders EYE PAIN subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0

OCULAR HYPERAEMIA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISTENSION			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
DIARRHOEA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
DYSPEPSIA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
IRRITABLE BOWEL SYNDROME			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
NAUSEA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
TOOTHACHE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
VOMITING			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
Skin and subcutaneous tissue disorders			
ACNE			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
ALOPECIA			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
DERMATITIS CONTACT			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 13 (7.69%) 1	0 / 1 (0.00%) 0
ECZEMA			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
NAIL BED INFLAMMATION			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
RASH			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
URTICARIA			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
Renal and urinary disorders			
BLADDER DISCOMFORT			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
BLADDER SPASM			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
DYSURIA			
subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
HAEMATURIA			

subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
LEUKOCYTURIA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
POLLAKIURIA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PROTEINURIA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
URETHRAL PAIN			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
URINARY INCONTINENCE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BACK PAIN			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
FLANK PAIN			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
JOINT SWELLING			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL CHEST PAIN			

subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>MUSCULOSKELETAL PAIN</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>MYALGIA</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>SACRAL PAIN</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>SPONDYLOLISTHESIS</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>Infections and infestations</b>			
<b>BACTERIURIA</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>EAR INFECTION</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>FUNGAL SKIN INFECTION</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>GASTROENTERITIS</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>GASTROENTERITIS VIRAL</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
<b>INFLUENZA</b>			
subjects affected / exposed	1 / 7 (14.29%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
<b>LARYNGITIS</b>			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

NASOPHARYNGITIS			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
PARONYCHIA			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PHARYNGITIS			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
RHINOVIRUS INFECTION			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
SINUSITIS			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
TONSILLITIS			
subjects affected / exposed	0 / 7 (0.00%)	1 / 13 (7.69%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
TRACHEOBRONCHITIS			
subjects affected / exposed	0 / 7 (0.00%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 7 (14.29%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
URINARY TRACT INFECTION			
subjects affected / exposed	2 / 7 (28.57%)	4 / 13 (30.77%)	0 / 1 (0.00%)
occurrences (all)	3	5	0
VIRAL INFECTION			
subjects affected / exposed	1 / 7 (14.29%)	0 / 13 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
VULVOVAGINAL CANDIDIASIS			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
Metabolism and nutrition disorders ABNORMAL WEIGHT GAIN subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0
VITAMIN D DEFICIENCY subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 13 (0.00%) 0	0 / 1 (0.00%) 0

<b>Non-serious adverse events</b>	All BOTOX Cycle 3	100 U BOTOX Cycle 4	All BOTOX Cycle 4
Total subjects affected by non-serious adverse events subjects affected / exposed	12 / 22 (54.55%)	1 / 3 (33.33%)	2 / 4 (50.00%)
Vascular disorders FLUSHING subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
HAEMATOMA subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
RAYNAUD'S PHENOMENON subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
General disorders and administration site conditions CHRONIC FATIGUE SYNDROME subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
FATIGUE subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
ILLNESS subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
MALAISE subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0

PAIN			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 22 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
PYREXIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
DYSMENORRHOEA			
subjects affected / exposed	2 / 22 (9.09%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
GENITAL PAIN			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HAEMORRHAGIC OVARIAN CYST			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HEAVY MENSTRUAL BLEEDING			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
OEDEMA GENITAL			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VAGINAL HAEMORRHAGE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL DISCOMFORT			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
NASAL CONGESTION			



subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
ANOREXIA NERVOSA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ANXIETY			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Investigations			
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD URINE PRESENT			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CRYSTAL URINE PRESENT			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CYTOMEGALOVIRUS TEST POSITIVE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EPSTEIN-BARR VIRUS TEST POSITIVE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELLS URINE POSITIVE			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
RESIDUAL URINE VOLUME			

subjects affected / exposed	0 / 22 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
URINE LEUKOCYTE ESTERASE POSITIVE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
ANIMAL BITE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ANIMAL SCRATCH			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
CLAVICLE FRACTURE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CONTUSION			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
FALL			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
JOINT INJURY			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LIGAMENT SPRAIN			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
POST PROCEDURAL DISCOMFORT			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PROCEDURAL PAIN			

subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
TENDON INJURY subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
Cardiac disorders TACHYCARDIA subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
Nervous system disorders DIZZINESS subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 2	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
HEADACHE subjects affected / exposed occurrences (all)	3 / 22 (13.64%) 4	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
MIGRAINE subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
Blood and lymphatic system disorders ANAEMIA subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
Ear and labyrinth disorders HYPERACUSIS subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
MISOPHONIA subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
Eye disorders EYE PAIN subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
OCULAR HYPERAEMIA subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0

Gastrointestinal disorders			
ABDOMINAL DISTENSION			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
DIARRHOEA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DYSPEPSIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
IRRITABLE BOWEL SYNDROME			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NAUSEA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TOOTHACHE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VOMITING			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			

ACNE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ALOPECIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DERMATITIS CONTACT			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
ECZEMA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NAIL BED INFLAMMATION			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RASH			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
URTICARIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
BLADDER DISCOMFORT			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLADDER SPASM			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DYSURIA			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HAEMATURIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LEUKOCYTURIA			

subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
POLLAKIURIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PROTEINURIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
URETHRAL PAIN			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
URINARY INCONTINENCE			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BACK PAIN			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
FLANK PAIN			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
JOINT SWELLING			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL PAIN			

subjects affected / exposed	0 / 22 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
MYALGIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SACRAL PAIN			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SPONDYLOLISTHESIS			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
BACTERIURIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EAR INFECTION			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
FUNGAL SKIN INFECTION			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
GASTROENTERITIS			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS VIRAL			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
LARYNGITIS			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NASOPHARYNGITIS			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0

PARONYCHIA			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PHARYNGITIS			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RHINOVIRUS INFECTION			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SINUSITIS			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TONSILLITIS			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
TRACHEOBRONCHITIS			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
URINARY TRACT INFECTION			
subjects affected / exposed	6 / 22 (27.27%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	8	0	0
VIRAL INFECTION			
subjects affected / exposed	1 / 22 (4.55%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
VULVOVAGINAL CANDIDIASIS			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			



ABNORMAL WEIGHT GAIN			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VITAMIN D DEFICIENCY			
subjects affected / exposed	0 / 22 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 February 2014	Amendment 1  Details were added to clarify primary analysis and final analysis details including unblinding after primary analysis.
05 September 2014	Amendment 2/Version 3  Exclusion criteria regarding medical conditions that may put patients at increased risk with exposure to BOTOX were inadvertently omitted in the original protocol and Amendment 1, these were added. Details from investigator's meeting were also added.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported